CHEK2 and cancer: There were no significant differences between BRAFV600E + CHEK2 and BRAFV600E mutation alone in sex, age at diagnosis, tumor size, PTC histological variant, multifocality, lymph node metastases, distant metastases, extrathyroidal extension, vascular invasion, or more advanced stage of cancer.